Compare American Superconductor Corporation (AMSC) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Superconductor Corporation vs Medpace Holdings Inc — how do they compare? American Superconductor Corporation trades at $35.49 (market cap $1.74B), while Medpace Holdings Inc trades at $538.23 (market cap $15.37B). The key difference: Medpace Holdings Inc is far larger — about 8.8× American Superconductor Corporation's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, American Superconductor Corporation nearer its low. Which is the better fit depends on your goals.
| AMSC | MEDP | |
|---|---|---|
Market Cap | $1.74B | $15.37B |
Sector | Technology | Technology |
52-Week High | $66.68 | $620.59 |
52-Week Low | $25.95 | $308.88 |
Enterprise Value | $1.61B | $14.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $35.96, down 3.26% today amid bearish technical signals. The stock shows strong fundamentals with recent earnings beats and robust profitability metrics including 44.73% net margin and 35.56% ROE. Revenue grew 34% year-over-year to $299.2 million in 2025, though cash flow trends show negative net cash flow of -$6.9M. Analyst sentiment remains positive with 53% buy ratings despite recent insider selling activity.
The outlook remains cautiously optimistic given strong order backlog growth of 40% and expanding role in AI energy infrastructure. Key risks include valuation concerns at 66.72x EV/EBITDA and acquisition-driven growth versus organic expansion. Earnings momentum and grid technology positioning provide upside potential if execution continues.
MEDP trades at $538.23, up 0.51% with a bullish technical signal and strong fundamentals. The stock shows robust profitability with 17.19% net margins and 77.25% ROE, though valuations appear elevated with a P/E of 33.87. Recent earnings consistently beat expectations, and 2026 projections indicate revenue growth to $2.7B. Technical analysis shows support at $527 and resistance at $543, with the current price near pivot point $535.
MEDP presents growth potential from strong CRO demand and earnings momentum, but faces risks from class action lawsuits and elevated valuation multiples. Analyst consensus is cautious with 74% hold ratings and a $479 price target below current levels. The stock's outlook depends on maintaining backlog quality amid rising cancellations and AI investment delays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
